<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32778129</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1465-993X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Aug</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Respiratory research</Title>
          <ISOAbbreviation>Respir Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>210</StartPage>
          <MedlinePgn>210</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">210</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12931-020-01477-y</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The effect of different concentrations of gefitinib on cell proliferation were evaluated using the CCK-8 assay. FGL1 expression in the normal human bronchial epithelial cell line Beas-2B, as well as four lung tumor cell lines, H1975, A549, PC9, and PC9/GR, was investigated by using western blotting and qRT-PCR. FGL1 was knocked down using small interfering RNA to evaluate the effects of FGL1 on PC9 and PC9/GR. The correlation between FGL1 expression and gefitinib resistance was determined in vitro via CCK-8 and colony formation assays, and flow cytometry and in vivo via flow cytometry and immunohistochemistry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">FGL1 expression was significantly upregulated in non-small cell lung cancer cells with EGFR mutation and higher in the gefitinib-resistant NSCLC cell line PC9/GR than in the gefitinib-sensitive NSCLC cell line PC9. Further, FGL1 expression in PC9 and PC9/GR cells increased in response to gefitinib treatment in a dose-dependent manner. Knockdown of FGL1 suppressed cell viability, reduced the gefitinib IC50 value, and enhanced apoptosis in PC9 and PC9/GR cells upon gefitinib treatment. Mouse xenograft experiments showed that FGL1 knockdown in PC9/GR tumor cells enhanced the inhibitory and apoptosis-inducing actions of gefitinib. The potential mechanism of gefitinib in inducing apoptosis of PC9/GR cells involves inhibition of PARP1 and caspase 3 expression via suppression of FGL1.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">FGL1 confers gefitinib resistance in the NSCLC cell line PC9/GR by regulating the PARP1/caspase 3 pathway. Hence, FGL1 is a potential therapeutic target to improve the treatment response of NSCLC patients with acquired resistance to gefitinib.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Cuilan</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Weiwei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jiatao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Jiqing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. haojiqing@ahmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Respir Res</MedlineTA>
        <NlmUniqueID>101090633</NlmUniqueID>
        <ISSNLinking>1465-9921</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C485894">FGL1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9001-32-5</RegistryNumber>
          <NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Apoptosis</Keyword>
        <Keyword MajorTopicYN="N">Epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">Fibrinogen-like-protein 1</Keyword>
        <Keyword MajorTopicYN="N">Gefitinib resistance</Keyword>
        <Keyword MajorTopicYN="N">Non-small cell lung cancer</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32778129</ArticleId>
        <ArticleId IdType="pmc">PMC7418324</ArticleId>
        <ArticleId IdType="doi">10.1186/s12931-020-01477-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s12931-020-01477-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al.  Cancer statistics in China 2015. CA Cancer J Clin. 2016;66:115–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28055103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. Clin Oncol. 2013;31:3987–3996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3805932</ArticleId>
            <ArticleId IdType="pubmed">24101047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20573926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:23–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22285168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu K, Li J, Qi Y, Zhang C, Zhu D, Liu D, et al.  SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. Biomed Pharmacother. 2019;116:1089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31121484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu W, Yuan Y, Pan Y-Y, Zhang Y. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Mol Med Rep. 2014;10:931–938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santarpia M, Menis J, Chaib I, Gonzalez Cao M, Rosell R. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Rev Clin Pharmacol. 2019;12:831–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31356117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asami K, Atagi S. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. Clin Oncol. 2014;5:646–659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4129529</ArticleId>
            <ArticleId IdType="pubmed">25302168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bracht JWP, Karachaliou N, Berenguer J, Pedraz-Valdunciel C, Filipska M, Codony-Servat C, et al.  Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC) Int J Biol Sci. 2019;15:2607–2614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6854375</ArticleId>
            <ArticleId IdType="pubmed">31754333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 2018;7:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6262543</ArticleId>
            <ArticleId IdType="pubmed">30445769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E. EMT: a mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:29–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30419315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, et al.  CD44 facilitates epithelial-to-mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer. Mol Cancer Ther. 2018;17:2257–2265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30049789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomasello C, Baldessari C, Napolitano M, Orsi G, Grizzi G, Bertolini F, et al.  Resistance to EGFR inhibitors in non-small cell lung cancer: clinical management and future perspectives. Crit Rev Oncol Hematol. 2018;123:149–161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29482776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng J. How to unleash mitochondrial apoptotic blockades to kill cancers? Acta Pharm Sin B. 2017;7:18–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5237704</ArticleId>
            <ArticleId IdType="pubmed">28119805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgillo F, Della Corte CM, Fasano M, Ciadiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5070275</ArticleId>
            <ArticleId IdType="pubmed">27843613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, et al.  Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307–1316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28919011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakelee HA, Gettinger S, Engelman J, Jänne PA, West H, Subramaniam DS, et al.  A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79:923–932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5403837</ArticleId>
            <ArticleId IdType="pubmed">28352985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Frittschen C, et al.  Emd 1214063 and Emd 1204831 constitute a new class of potent and highly selective C-met inhibitors. Clin Cancer Res. 2013;19:2941–2951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23553846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapyin non-small-cell lung cancer. Ecancermedicalscience. 2016;10:648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4929979</ArticleId>
            <ArticleId IdType="pubmed">27433281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X, Guan A, Chen X, Xiao J, Xie M, Yang B, et al.  mPRα mediates P4/org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway. Mol Carcinog. 2020;59:179–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31777985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, et al.  Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci. 2018;109:3183–3196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6172047</ArticleId>
            <ArticleId IdType="pubmed">30098066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, et al.  SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res. 2017;77:2990–3000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5467531</ArticleId>
            <ArticleId IdType="pubmed">28416483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, et al.  Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. J Natl Cancer Inst. 2017;109:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5409000</ArticleId>
            <ArticleId IdType="pubmed">28376152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, et al.  Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014;4:606–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4011693</ArticleId>
            <ArticleId IdType="pubmed">24535670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, et al.  The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest. 2011;121:2102–2110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3104768</ArticleId>
            <ArticleId IdType="pubmed">21633178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4629442</ArticleId>
            <ArticleId IdType="pubmed">26579470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Ukomadu C. Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactant. Biochem Biophys Res Commun. 2008;365:729–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2288651</ArticleId>
            <ArticleId IdType="pubmed">18039467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al.  Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176:334–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6365968</ArticleId>
            <ArticleId IdType="pubmed">30580966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CY, Cao CZ, Xu WX, Cao MM, Yang F, Dong L, et al.  Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failure. Gut. 2010;59:817–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19880967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayeb-Hashemi H, Desai A, Demchev V, Bronson RT, Hornick JM, Cohen DE, et al.  Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development. Biochem Biophys Res Commun. 2015;465:167–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4594872</ArticleId>
            <ArticleId IdType="pubmed">26225745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J, Ying H, Gu F, He J, Li LY, Liu HM, et al.  Cloning and characterization of a mouse liver-specific gene mfrep-1, up-regulated in liver regeneration. Cell Res. 2002;12:353–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12528893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuo ZL, Cai YJ, Chen Y, Chen S, Liu LY, Shen ZH, et al.  Bone marrow-derived mesenchymal stem cells attenuate acute liver injury and regulate the expression of fibrinogen-like-protein 1 and signal transducer and activator of transcription 3. Mol Med Rep. 2015;12:2089–2097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25901902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bie F, Wang G, Qu X, Wang Y, Huang C, Wang Y, et al.  Loss of FGL1 induces epithelial-mesenchymal transition and angiogenesis in LKB1 mutant lung adenocarcinoma. Int J Oncol. 2019;55:697–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31322182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fausto N. Liver regeneration. J Hepatol. 2000;32:19–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10728791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu HT, Yu M, Li CY, Zhan YQ, Xu WX, Li YH, et al.  Specific expression and regulation of hepassocin in the liver and down-regulation of the correlation of HNF1alpha with decreased levels of hepassocin in human hepatocellular carcinoma. Biol Chem. 2009;284:13335–13347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2679433</ArticleId>
            <ArticleId IdType="pubmed">19304666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Meyer CA, Fei T, Wang G, Zhang F, Liu XS, et al.  A systematic approach identifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-to-mesenchymal Tran- sition in lung cancer. BMC Genomics. 2013;14:680.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3852829</ArticleId>
            <ArticleId IdType="pubmed">24093963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Qiao HX, Zhou YT, et al.  Fibrinogen-like-protein 1 promotes the invasion and metastasis of gastric cancer and is associated with poor prognosis. Mol Med Rep. 2018;18:1465–1472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6072172</ArticleId>
            <ArticleId IdType="pubmed">29845203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Gao W, Hao J. Mechanism of FGL1 regulates the migration and invasion of PC9/GR cells of non-small cell lung cancer. Chin Pharmacol Bull. 2020;36:991–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Cao MM, Xu WX, Li CY, Cao CZ, Wang ZD, Yao JW, et al.  Hepassocin regulates cell proliferation of the human hepatic cells L02 and hepatocarcinoma cells through different mechanisms. J Cell Biochem. 2011;112:2282–2290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21618590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Zhou X, Mei J, Geng X, Zhou Y, Zhang W, et al.  Study on the activity of the signaling pathways regulating hepatocytes from G0 phase into G1 phase during rat liver regeneration. Cell Mol Biol Lett. 2014;19:181–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6275877</ArticleId>
            <ArticleId IdType="pubmed">24643584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Da Silva CG, Studer P, Skroch M, et al.  A20 promotes liver Regen- eration by decreasing SOCS3 expression to enhance IL-6/STAT3 proliferative signals. Hepatology. 2013;57:2014–2025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3626749</ArticleId>
            <ArticleId IdType="pubmed">23238769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Long S, Xiao S, Wu W, Hann SS. Decoction of Chinese herbal medicine Fuzheng Kang-ai induces lung cancer cell apoptosis via STAT3/Bcl-2/Caspase-3 pathway. Evid Based Complement Alternat Med. 2018;2018:8567905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6036821</ArticleId>
            <ArticleId IdType="pubmed">30046347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, et al.  Acquired resistance of EGFR-mutated lung cancer to tyrosine kinase inhibitor treatment promotes PARP inhibitor sensitivity. Cell Rep. 2019;5:320–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6624074</ArticleId>
            <ArticleId IdType="pubmed">31216465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 2002;277:28411–28417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12032149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Zhan Y-Q, Yu M, Ge C-H, Li C-Y, Zhang J-H, et al.  Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway. Cell Signal. 2014;26:2161–2166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24768768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park HJ, Min TR, Chi GY, Choi YH, Park SH. Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation. Biochem Biophys Res Commun. 2018;505:194–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30243717</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
